Zacks Research Issues Negative Outlook for Alkermes Earnings

Alkermes plc (NASDAQ:ALKS) – Stock analysts at Zacks Research decreased their Q2 2025 EPS estimates for Alkermes in a report released on Monday, January 6th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.31 for the quarter, down from their previous forecast of $0.33. The consensus estimate for Alkermes’ current full-year earnings is $2.25 per share. Zacks Research also issued estimates for Alkermes’ Q3 2025 earnings at $0.33 EPS, Q4 2025 earnings at $0.36 EPS, Q1 2026 earnings at $0.35 EPS and FY2026 earnings at $1.56 EPS.

Several other equities research analysts also recently issued reports on ALKS. Stifel Nicolaus upgraded Alkermes from a “hold” rating to a “buy” rating and increased their target price for the stock from $25.00 to $36.00 in a research report on Tuesday, November 5th. JPMorgan Chase & Co. cut their target price on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Piper Sandler reiterated an “overweight” rating and set a $37.00 price target (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. The Goldman Sachs Group lowered their price target on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Finally, Mizuho boosted their price objective on shares of Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $36.00.

Alkermes Stock Up 0.2 %

ALKS opened at $28.54 on Wednesday. Alkermes has a 12 month low of $22.90 and a 12 month high of $32.88. The company has a market cap of $4.62 billion, a PE ratio of 14.64, a price-to-earnings-growth ratio of 1.03 and a beta of 0.49. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. The company has a 50 day moving average of $29.17 and a 200 day moving average of $27.63.

Hedge Funds Weigh In On Alkermes

Large investors have recently added to or reduced their stakes in the business. Diversified Trust Co grew its stake in shares of Alkermes by 11.5% during the fourth quarter. Diversified Trust Co now owns 42,509 shares of the company’s stock valued at $1,223,000 after buying an additional 4,378 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Alkermes by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 120,006 shares of the company’s stock valued at $3,486,000 after acquiring an additional 2,903 shares during the period. Tidal Investments LLC bought a new position in Alkermes during the 3rd quarter worth approximately $1,098,000. Wilmington Savings Fund Society FSB purchased a new position in Alkermes in the 3rd quarter worth approximately $582,000. Finally, Sanctuary Advisors LLC increased its stake in Alkermes by 254.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock worth $944,000 after purchasing an additional 23,541 shares during the period. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insider Buying and Selling

In related news, SVP Christian Todd Nichols sold 5,208 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the sale, the senior vice president now owns 60,703 shares in the company, valued at $1,769,492.45. The trade was a 7.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Craig C. Hopkinson sold 10,471 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $29.53, for a total transaction of $309,208.63. Following the transaction, the executive vice president now owns 99,238 shares in the company, valued at $2,930,498.14. The trade was a 9.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 147,738 shares of company stock worth $4,572,904. Corporate insiders own 4.89% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.